Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 5
- Profitability 95
- Business Quality 75
- Balance Sheet 30
- Cash Flow 80
Why this rating?
Health 45/100 — Speculative
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Xeris Biopharma Holdings, Inc. (XERS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Xeris Biopharma Holdings, Inc. 45/100 (Speculative) due to high business quality, strong revenue growth, and elevated leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Stretched
- Valuation Fair
Financial highlights
Valuation
- Forward P/E 21.74
- EV/Revenue 5.14
Profitability
- Revenue Growth 28.7%
- Gross Margin 86.6%
- Operating Margin 5.6%
- Net Margin -5.1%
Financial strength
- Cash $121.75M
- Debt $289.44M
- Net Cash $-167.69M
- Free Cash Flow $27.93M
- Current Ratio 1.45
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$9.06 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$73.56 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Neurocrine Biosciences, Inc. Drug Manufacturers - Specialty & Generic NBIX$155.13 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Lantheus Holdings, Inc. Drug Manufacturers - Specialty & Generic LNTH$100.44 70 Health 70 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$12.43 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$45.49 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Hims & Hers Health, Inc. Drug Manufacturers - Specialty & Generic HIMS$28.17 61 Health 61 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Supernus Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic SUPN$42.43 60 Health 60 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Xeris Biopharma Holdings, Inc. (XERS).